Search results for "COMB"

showing 10 items of 7115 documents

Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo

1996

The present study was designed to investigate in vivo immunomodulatory properties of hematopoietic growth factors. The influence on the activation of cytokine synthesis and on the expression of surface antigens associated with cellular activation of G-CSF or GM-CSF was investigated in cancer patients receiving these factors. One single dose of growth factor was administered to patients with bladder cancer (G-CSF group) or small cell lung cancer (GM-CSF group) before chemotherapy. After cytoreductive chemotherapy patients received supportive therapy with G-CSF or GM-CSF. Peripheral blood mononuclear cells and plasma samples were obtained for flow cytometry, Northern blot analysis, and assess…

AdultSialoglycoproteinsmedicine.medical_treatmentBiologyPeripheral blood mononuclear cellAdjuvants ImmunologicGranulocyte Colony-Stimulating FactormedicineHumansRNA MessengerGrowth SubstancesInterleukin 6AgedInterleukin-6MonocyteGrowth factorInterleukin-8Granulocyte-Macrophage Colony-Stimulating FactorReceptors Interleukin-1Receptors Interleukin-2HematologyGeneral MedicineMiddle AgedHematopoietic Stem CellsRecombinant ProteinsGranulocyte colony-stimulating factorInterleukin 1 Receptor Antagonist ProteinHaematopoiesisGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureCytokineSolubilityAntigens SurfaceImmunologyCancer researchbiology.proteinmedicine.drugAnnals of Hematology
researchProduct

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

2015

To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed.Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)).Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS.…

AdultTertiary Care CenterCarcinoma Ovarian EpithelialDisease-Free SurvivalcytoreductionTertiary Care CentersOvarian cancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasms Glandular and EpithelialAgedNeoplasm StagingAged 80 and overOvarian NeoplasmsCytoreduction; Interval debulking surgery; Ovarian cancer; PrognosisClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmMiddle AgedPrognosisNeoadjuvant TherapySettore MED/40 - GINECOLOGIA E OSTETRICIAinterval debulking surgeryFemaleprognosineoadjuvant chemotherapyHuman
researchProduct

Vesico-uterine fistula treated by amenorrhoea induced with contraceptive steroids. Two case reports.

1980

2 case reports of women with vesico-uterine fistulae who were successfully treated by inducing amenorrhea by the continuous administration of an estrogen-progestogen compound for 6 months are presented. Ortho-Novum 1/50 was used. The amenorrheic condition induced by continuous ingestion of an oral contraceptive agent allowed the fistula time to heal since fistulae rarely close spontaneously because of fluids flowing fhrough them inhibiting the healing process. This method of management should be tried before surgery the generally recommended treatment.

AdultUterine Diseasesmedicine.medical_specialtyFistulabusiness.industryUrinary Bladder FistulaResearch methodologyFistulaObstetrics and GynecologyUterine Fistulamedicine.diseaseOral contraceptive agentSurgeryContraceptives Oral CombinedFamily planningmedicineHumansAmenorrheaFemalemedicine.symptombusinessAmenorrheaContraceptives OralBritish journal of obstetrics and gynaecology
researchProduct

Combined use of uterine artery embolization and local methotrexate injection in interstitial ectopic pregnancies with poor prognosis.

2009

Objective To report three cases of interstitial pregnancies treated successfully by combining uterine artery embolization (UAE) and ultrasound-guided local administration of methotrexate (MTX); and to assess the effect of UAE on ovarian reserve by prospectively measuring serum antimullerian hormone (AMH) levels. Design Case report. Setting Departments of obstetrics and gynecology and radiology of a university hospital. Patient(s) Three patients with interstitial pregnancy. Treatment with multiple IM injections of MTX had failed in cases 1 and 3. Case 2 presented high initial serum β-hCG levels (93,563 mIU/mL), suggesting the presence of a substantial amount of trophoblastic tissue. Interven…

Adultendocrine systemPoor prognosismedicine.medical_specialtymedicine.medical_treatmentCombined useUterine artery embolizationObstetrics and gynaecologyPregnancymedicineHumansOvarian reservePregnancybusiness.industryObstetricsObstetrics and GynecologyUterine Artery Embolizationmedicine.diseasePrognosisCombined Modality TherapyPregnancy EctopicMethotrexateReproductive MedicineMethotrexateInterstitial pregnancyFemalebusinessmedicine.drugFertility and sterility
researchProduct

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vi…

2007

Objective: To investigate the effects of recombinant (r-) LH supplementation in “low responder” patients undergoing ovarian stimulation with r-FSH for an IVF program. The apoptosis rate in cumulus cells was used as an indicator of oocyte quality. Design: Comparison of the rate of DNA fragmentation and caspase-3 activity in cumulus cells in women stimulated with r-LH and r-FSH, versus patients treated with r-FSH alone (control). Setting: In vitro fertilization (IVF) laboratory. Patient(s): Forty patients undergoing assisted fertilization programs treated with a GnRH agonist, or r-FSH treatment begun on day 3 of the cycle (control). In the r-LH group, from day 8 of gonadotropin stimulation, 1…

Adultendocrine systemmedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentOvaryApoptosisDNA FragmentationFertilization in VitroBiologyOvulation InductionPregnancyInternal medicinemedicineIn Situ Nick-End LabelingHumansrecombinant LHOvarian follicleimplantation rateHuman cumulus cells; apoptosis; IVF; pregnancy rate; implantation rate; recombinant LH; oocyte qualityIn vitro fertilisationGranulosa CellsCaspase 3Obstetrics and GynecologyLuteinizing HormoneOocyteCumulus oophorusapoptosiRecombinant ProteinsPregnancy ratemedicine.anatomical_structureEndocrinologyHuman cumulus cellReproductive MedicineIVFFemaleoocyte qualityGonadotropinFollicle Stimulating HormoneLuteinizing hormonehormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.

2011

High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH con…

Adultendocrine systemmedicine.medical_specialtymedicine.medical_treatmentStimulationlaw.inventionGonadotropin-Releasing HormoneOvulation InductionlawInternal medicineFollicular phaseMedicineHumansProspective StudiesAdverse effectProspective cohort studyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyLuteinizing HormoneRecombinant ProteinsDose–response relationshipEndocrinologyReproductive MedicineRecombinant DNAOvulation inductionFemalebusinesshormones hormone substitutes and hormone antagonistsDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Physical fitness profile in female horseback riders.

2019

BACKGROUND: The purpose of the present study was to examine the levels of endurance and neuromuscular performance variables in female horseback riders. METHODS: 52 female Finnish riders were involved (age 29.4±8.9 yrs, height 1.68±0.06 m, weight 67.5±10.0 kg), 19 show-jumping riders (SJ) and 33 eventing riders (E), riding-time minimum of 4 times/week, jumping level of minimum 1.06±0.11m. The measurements were maximal bilateral isometric leg press force (MVCLP), maximal unilateral isometric knee extension (MVCKE) and flexion forces (MVCKF), countermovement jump (CMJ), maximal isometric force of the trunk extensor and flexor muscles (MVCE, MVCF), weight distribution of the body (WD), handgrip…

Adultkestävyysharjoittelu040301 veterinary sciencesStrength trainingPhysical Therapy Sports Therapy and Rehabilitationcombined strength and endurance trainingIsometric exercisemedicine.disease_cause0403 veterinary science03 medical and health sciencesYoung Adultratsastajat0302 clinical medicineJumpingAnimal scienceendurance traininghevosurheiluratsastusHand strengthequestrian sportsstrength trainingmedicineHumansOrthopedics and Sports MedicineMuscle StrengthLeg pressMuscle SkeletalHand Strengthbusiness.industryLactate thresholdVO2 maxResistance Training030229 sport sciences04 agricultural and veterinary sciencesTrunkfyysinen kuntoAthletesPhysical Fitnesshorseback ridingPhysical EnduranceFemalevoimaharjoittelubusinessSportsThe Journal of sports medicine and physical fitness
researchProduct

Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris

1996

Percutaneous transluminal coronary angioplasty is often complicated by thrombotic abrupt vessel closure in patients with unstable angina pectoris. The present multicentre trial was performed to determine the feasibility of two-dose regimens of recombinant hirudin (r-hirudin) compared to standard heparin in patients undergoing coronary angioplasty for unstable angina, and to investigate the effects of the different treatment regimen on markers of coagulation activation. At five participating centres, 61 patients were randomly enrolled in one of two sequential groups of r-hirudin (group 1: 0.3 mg.kg-1 i.v. bolus, 0.12 mg.kg-1.h-1 i.v. infusion; 21 patients; group 2: 0.5 mg.kg-1 i.v. bolus, 0.…

Adultmedicine.drug_classmedicine.medical_treatmentHirudinEnzyme-Linked Immunosorbent AssayAnginaFibrinolytic AgentsmedicineHumansAngina UnstableAngioplasty Balloon CoronaryInfusions IntravenousBlood CoagulationAgedBlood coagulation testDose-Response Relationship Drugmedicine.diagnostic_testHeparinUnstable anginabusiness.industryAnticoagulantThrombinAnticoagulantsPercutaneous coronary interventionHeparinHirudinsMiddle Agedmedicine.diseaseRecombinant ProteinsAnesthesiaPartial Thromboplastin TimeDrug MonitoringCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugPartial thromboplastin timeEuropean Heart Journal
researchProduct

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss…

2003

Objective To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL). Methods We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the th…

Adultmedicine.medical_specialtyAbortion HabitualAdolescentmedicine.drug_classImmunologyLow molecular weight heparinGastroenterologyRoute of administrationRandom AllocationRheumatologyAntiphospholipid syndromePregnancyInternal medicinemedicineImmunology and AllergyHumansPharmacology (medical)PregnancyLupus anticoagulantAspirinAspirinbusiness.industryAnticoagulantPregnancy OutcomeAnticoagulantsImmunoglobulins IntravenousHeparinHeparin Low-Molecular-Weightmedicine.diseaseAntiphospholipid SyndromeSurgeryPregnancy ComplicationsTreatment OutcomeDrug Therapy CombinationFemalebusinessmedicine.drugArthritis and rheumatism
researchProduct

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 y…

2009

This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines, Cervarix (GlaxoSmithKline) and Gardasil (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n = 1106) were stratified by age (18-26, 27-35, 36-45 years) and randomized (1:1) to receive Cervarix (Months 0, 1, 6) or Gardasil (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum neutralizing antibodies, as measured by pseudovirion-based neutralization assay (PBNA…

Adultmedicine.medical_specialtyAdolescentImmunologyAntibodies ViralCancer VaccinesSerologyYoung AdultHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Neutralization TestsInternal medicinemedicineHumansPapillomavirus VaccinesGeneral Pharmacology Toxicology and PharmaceuticsNeutralizing antibodyPapillomaviridaeCervical cancerbiologybusiness.industryImmunogenicityGardasilPapillomavirus InfectionsMiddle Agedmedicine.diseaseAntibodies NeutralizingVaccinationImmunologyCohortbiology.proteinFemaleCervarixbusinessmedicine.drugHuman Vaccines
researchProduct